Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.
- We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.
- In a Phase 2a study dipraglurant met its primary endpoint by being generally well tolerated and showing no clinically significant safety issues.
- However, the development of dyskinesia which may be associated with long-term use of levodopa can become as disabling as the symptoms of Parkinson's disease.
- Addexs lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) is in a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID).